Biocryst Pharmaceuticals (BCRX) Cost of Revenue (2012 - 2026)

Biocryst Pharmaceuticals has reported Cost of Revenue for 15 years, with the latest figure at $5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 17.71% year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $19.9 million (up 27.69% YoY), and the FY2025 full-year result was $19.1 million, up 55.47% from the prior year.
• Cost of Revenue for Q1 2026 stood at $5.4 million, down from $9.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $9.5 million in Q4 2025, with the low at $236000.0 in Q1 2022.
• Historically, Cost of Revenue has averaged $2.8 million across 5 years, with a median of $2.2 million in 2025.
• The largest YoY upside for Cost of Revenue was 499.49% in 2022 against a maximum downside of 96.02% in 2022.
• Biocryst Pharmaceuticals' Cost of Revenue stood at $2.4 million in 2022, then sank by 34.66% to $1.6 million in 2023, then soared by 291.39% to $6.1 million in 2024, then soared by 56.25% to $9.5 million in 2025, then tumbled by 43.53% to $5.4 million in 2026.
• The last three Cost of Revenue figures came in at $5.4 million (Q1 2026), $9.5 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.